AU2003218063A1 - Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist - Google Patents

Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist

Info

Publication number
AU2003218063A1
AU2003218063A1 AU2003218063A AU2003218063A AU2003218063A1 AU 2003218063 A1 AU2003218063 A1 AU 2003218063A1 AU 2003218063 A AU2003218063 A AU 2003218063A AU 2003218063 A AU2003218063 A AU 2003218063A AU 2003218063 A1 AU2003218063 A1 AU 2003218063A1
Authority
AU
Australia
Prior art keywords
mglu2
psychoses
therapy
combining
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003218063A
Other languages
English (en)
Inventor
Bryan Glenn Johnson
Darryle Darwin Schoepp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2003218063A1 publication Critical patent/AU2003218063A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2003218063A 2002-04-03 2003-03-21 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist Abandoned AU2003218063A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36977102P 2002-04-03 2002-04-03
US36979702P 2002-04-03 2002-04-03
US60/369,771 2002-04-03
US60/369,797 2002-04-03
PCT/US2003/007283 WO2003084610A1 (en) 2002-04-03 2003-03-21 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist

Publications (1)

Publication Number Publication Date
AU2003218063A1 true AU2003218063A1 (en) 2003-10-20

Family

ID=28794376

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003218063A Abandoned AU2003218063A1 (en) 2002-04-03 2003-03-21 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist

Country Status (5)

Country Link
EP (1) EP1492595A1 (ja)
JP (1) JP2005528378A (ja)
AU (1) AU2003218063A1 (ja)
CA (1) CA2478227A1 (ja)
WO (1) WO2003084610A1 (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1517915B1 (en) * 2002-06-11 2009-01-21 Eli Lilly And Company Prodrugs of excitatory amino acids
AU2008200612B8 (en) * 2002-06-11 2011-03-10 Eli Lilly And Company Prodrugs of excitatory amino acids
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0816767B8 (pt) 2007-09-14 2021-05-25 Addex Pharmaceuticals Sa composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
AU2009289784B2 (en) 2008-09-02 2012-03-22 Addex Pharma S.A. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
US8946205B2 (en) 2009-05-12 2015-02-03 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
MY161325A (en) 2009-05-12 2017-04-14 Janssen Pharmaceuticals Inc 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
US9296710B2 (en) 2011-06-17 2016-03-29 Eli Lilly And Company Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102461134B1 (ko) 2014-01-21 2022-10-28 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
UA121965C2 (uk) 2014-01-21 2020-08-25 Янссен Фармацевтика Нв Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof

Also Published As

Publication number Publication date
EP1492595A1 (en) 2005-01-05
WO2003084610A1 (en) 2003-10-16
JP2005528378A (ja) 2005-09-22
CA2478227A1 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
AU2003218063A1 (en) Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2003243637A1 (en) Cannabinoid receptor agonists
AU2003244802A1 (en) Videoconferencing apparatus
AU2003272329A1 (en) Privacy service
EP1499306A4 (en) BICYCLIC AMIDE
AU2003302799A1 (en) Video quality measurement
AU2003218005A1 (en) Substituted amides active at the cannabinoid-1 receptor
AU2003231240A1 (en) Portable corral apparatus
AU2003241836A1 (en) Lpa receptor antagonists
AU2003259295A1 (en) Self-contained hinge for flip-style device
AU2003238597A1 (en) Benzimidazole compounds and their use as estrogen agonists/antagonists
AU2002361742A1 (en) Parental analgesic formulations comprising fentanyl and a cannabinoid receptor agonist
AU2003242273A1 (en) Screw supplying device
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003225027A1 (en) Combination therapy using a ppar alpha/gamma agonist
AU2003249722A1 (en) Therapeutic amides
AU2003301216A1 (en) Novel use of liver x receptor agonists
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
EP1363046A3 (en) Ball screw apparatus
AU2003286251A1 (en) New bicyclic angiotensin ii agonists
AU2003277552A1 (en) Receptor regulator
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003251627A1 (en) Carvedilol hydrobromide
EP1420263A3 (en) Voltage standard apparatus

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase